(Q36614435)

English

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.

scientific article published on 30 May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Diana Giannarelli

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Serena Di Cosimo

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

G Ferretti

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

A Felici

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

P Papaldo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

A Fabi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

E M Ruggeri

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

M Milella

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

M Ciccarese

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

F L Cecere

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

A Gelibter

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

C Nuzzo

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

F Cognetti

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

E Terzoli

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

P Carlini

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

0 references

publication date

30 May 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

British Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

94

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1789-1796

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603194

0 references

New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

A summary of second-line randomized studies of aromatase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Quantitative methods in the review of epidemiologic literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Can meta-analyses be trusted?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

The control of breast cancer: the role of tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

30 September 2017

Inter-study differences: how should they influence the interpretation and analysis of results?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

28 June 2018

Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361349

20 September 2018

Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603194

21 January 2018

Assessment of response to treatment in advanced breast cancer. British Breast Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Why do we need systematic overviews of randomized trials?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of statistical methods for combining event rates from clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16736002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603194

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16736002%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36614435&oldid=2108743735"